Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Non-interventional Study to Describe the Effectiveness and Safety of Venetoclax in Acute Myeloid Leukemia (AML) Patients in Routine Clinical Practice (REVIVE Study)

NCT03987958 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT03987958
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03987958 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Non-interventional Study to Describe the Effectiveness and Safety of Venetoclax in Acute Myeloid Leukemia (AML) Patients in Routine Clinical Practice (REVIVE Study)
Lead sponsor
AbbVie
Phase
Observational
Overall status
Active, not recruiting
Start date
August 8, 2019
Completion date
July 31, 2027
Enrollment
100 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia